ESMO Congress | Conference

Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma

October 19th 2025

Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

Chemotherapy Plus Durvalumab, Bevacizumab, and Olaparib Fails to Offer OS Benefit in Newly Diagnosed Non-tBRCA–Mutated Ovarian Cancer

October 19th 2025

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Atezolizumab Plus Chemotherapy Demonstrates Noninferior Survival Vs Chemotherapy Alone in Advanced/Recurrent Endometrial Cancer

October 19th 2025

The addition of atezolizumab to chemotherapy demonstrated noninferior survival vs chemotherapy alone in advanced or recurrent endometrial cancer.

Enzalutamide Plus Leuprolide Yields OS Benefit in High-Risk, Biochemically Recurrent Prostate Cancer

October 19th 2025

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC

October 19th 2025

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

Sacituzumab Govitecan Reduces Risk of Progression or Death by 38% in PD-1/PD-L1–Ineligible TNBC

October 19th 2025

Sacituzumab govitecan reduced the risk for disease progression or death by 38% vs chemotherapy in previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer.

Capivasertib Plus Abiraterone Acetate, Prednisone, and ADT Extends rPFS in PTEN-Deficient HSPC

October 19th 2025

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

TUB-040 Yields Responses Across Dose Levels in Platinum-Resistant High-Grade Serous Ovarian Cancer

October 19th 2025

NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.

Infinatamab Deruxtecan Shows Encouraging CNS Activity in Extensive-Stage Small Cell Lung Cancer

October 19th 2025

I-DXd showed intracranial efficacy and manageable safety in ES-SCLC with brain metastases, per data from the IDeate-Lung01 study.

Pembrolizumab/Lenvatinib Combo Is Active, Safe in Uveal Melanoma

October 19th 2025

Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.

Gedatolisib Plus Fulvestrant ± Palbociclib Drives PFS Improvement in PIK3CA Wild-Type, HR+/HER2– Advanced Breast Cancer

October 19th 2025

Gedatolisib plus fulvestrant, with or without palbociclib, improved PFS in pretreated, HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer

October 19th 2025

Sac-TMT bested chemotherapy in terms of PFS in previously treated HR+, HER2– metastatic breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC

October 18th 2025

Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Neoadjuvant T-DXd Plus THP Yields pCR Benefit in High-Risk, HER2+ Early-Stage Breast Cancer

October 18th 2025

Neoadjuvant T-DXd followed by THP improved pathological complete response rate in high-risk, HER2-positive early-stage breast cancer.

Consolidation Tiragolumab/Atezolizumab Does Not Yield PFS Advantage in Stage III NSCLC

October 18th 2025

The SKYSCRAPER-03 trial missed the end point of a PFS benefit with tiragolumab plus atezolizumab vs durvalumab consolidation in advanced NSCLC.

Pembrolizumab Plus Paclitaxel +/– Bevacizumab Yields Survival Advantages in Recurrent PROC

October 18th 2025

Pembrolizumab and paclitaxel with or without bevacizumab led to PFS and OS benefits vs placebo in place of pembrolizumab in recurrent, PD-L1–positive PROC.

Tarlatamab Improves OS vs Chemotherapy in SCLC, Regardless of Prior PD-(L)1 Therapy or CFI Duration

October 18th 2025

Findigs from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Invikafusp Alfa Boasts High Disease Control Rate in Checkpoint Inhibitor–Resistant Solid Tumors

October 18th 2025

Invikafusp alfa demonstrated early signals of antitumor activity across a range of biomarker-enriched patients with solid tumors.

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma

October 18th 2025

Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease

October 18th 2025

T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.